Trevi Therapeutics (TRVI) Receives a Buy from Needham

Needham analyst Serge Belanger maintained a Buy rating on Trevi Therapeutics (TRVIResearch Report) today and set a price target of $12.00. The company’s shares closed last Thursday at $3.50.

According to, Belanger is a 1-star analyst with an average return of -0.5% and a 38.0% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Trevi Therapeutics with a $11.33 average price target.

See today’s analyst top recommended stocks >>

Based on Trevi Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $7.38 million. In comparison, last year the company had a GAAP net loss of $7.35 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson’s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.